文献速递肿瘤 PET/CT核素与放射性配体治疗

基于[18F]PSMA-1007 PET的RECIP 1.0在经[177Lu]Lu-PSMA I&T治疗前列腺癌患者中的预后性能

Prognostic Performance of RECIP 1.0 Based on [18F]PSMA-1007 PET in Prostate Cancer Patients Treated with [177Lu]Lu-PSMA I&T.
PubMed 文献 · J Nucl Med · 2024-04-01

回顾性分析73例接受177Lu-PSMA I&T治疗并在2周期前后行18F-PSMA-1007 PET/CT的转移性去势抵抗性前列腺癌患者,评估RECIP 1.0对总生存的预后价值并与基于PSA的PCWG3标准比较。中位随访14个月,中位OS 15个月;ΔPSA和多变量分析中均为独立预后因素,RECIP 1.0单独区分PD未达统计学显著(P=0.08),联合PCWG3与RECIP 1.0区分无PD与PD最佳(19个月 vs 8个月;HR 2.78)。

要点

  • RECIP 1.0单独用于18F-PSMA-1007 PET区分PD与无PD未达统计学显著(P=0.08)。
  • ΔPSA在多变量Cox分析中为OS的独立预后因素(每百分比HR 1.004;95%CI 1.001-1.006;P=0.006)。
  • 联合PCWG3与RECIP 1.0区分无PD与PD最佳(19个月 vs 8个月;HR 2.78;95%CI 1.32-5.86;P=0.002)。

核心结论

  • 在经RLT治疗并接受18F-PSMA-1007 PET/CT成像的mCRPC患者中,整合生化(PCWG3)与PET(RECIP 1.0)应答框架可能最有助于识别易发生疾病进展的个体。

研究设计与样本

  • 回顾性分析73例转移性去势抵抗性前列腺癌患者,均在RLT 2周期前后接受18F-PSMA-1007 PET/CT扫描。
  • 计算血清PSA水平变化(ΔPSA)及全身肿瘤负荷定量PET参数(SUVmean、SUVmax、PSMA肿瘤体积、总病灶PSMA)。
  • 按PCWG3标准对ΔPSA分类,按RECIP 1.0对PET成像应答分类。
  • 行单变量Cox回归分析,随后行多变量及Kaplan-Meier分析。

主要发现

  • 中位OS为15个月,中位随访时间为14个月。
  • 单变量Cox回归分析显示ΔPSA(每百分比HR 1.004;95%CI 1.002-1.007;P<0.001)和PSMA肿瘤体积(每单位HR 1.003;95%CI 1.000-1.005;P=0.03)与OS显著相关。
  • 多变量Cox回归分析证实ΔPSA(每百分比HR 1.004;95%CI 1.001-1.006;P=0.006)为OS的独立预后因素。
  • Kaplan-Meier分析显示任何PSA应答者与无PSA应答者间分离显著(19个月 vs 14个月;HR 2.00;95%CI 0.95-4.18;P=0.04)。
  • 应用PSA-based PCWG3区分无PD与PD可行(19个月 vs 9个月;HR 2.29;95%CI 1.03-5.09;P=0.01),而应用RECIP 1.0稍未达统计学显著(P=0.08)。

关键数值与推荐

  • RECIP 1.0基于68Ga和18F标记PET显像剂,对接受PSMA靶向RLT的mCRPC患者提供除PSA变化之外的预后信息。
  • PCWG3标准用于ΔPSA分类,RECIP 1.0用于PET成像应答分类。
  • 单变量Cox回归中ΔPSA每百分比HR 1.004(95%CI 1.002-1.007;P<0.001),PSMA肿瘤体积每单位HR 1.003(95%CI 1.000-1.005;P=0.03)。
  • 多变量Cox回归中ΔPSA每百分比HR 1.004(95%CI 1.001-1.006;P=0.006)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In metastatic castration-resistant prostate cancer (mCRPC) patients treated with prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), the recently proposed criteria for evaluating response to PSMA PET (RECIP 1.0) based on 68Ga- and 18F-labeled PET agents provided prognostic information in addition to changes in prostate-specific antigen (PSA) levels. Our aim was to evaluate the prognostic performance of this framework for overall survival (OS) in patients undergoing RLT and imaged with [18F]PSMA-1007 PET/CT and compare the prognostic performance with the PSA-based response assessment. Methods: In total, 73 patients with mCRPC who were scanned with [18F]PSMA-1007 PET/CT before and after 2 cycles of RLT were retrospectively analyzed. We calculated the changes in serum PSA levels (ΔPSA) and quantitative PET parameters for the whole-body tumor burden (SUVmean, SUVmax, PSMA tumor volume, and total lesion PSMA). Men were also classified following the Prostate Cancer Working Group 3 (PCWG3) criteria for ΔPSA and RECIP 1.0 for PET imaging response. We performed univariable Cox regression analysis, followed by multivariable and Kaplan-Meier analyses. Results: Median OS was 15 mo with a median follow-up time of 14 mo. Univariable Cox regression analysis provided significant associations with OS for ΔPSA (per percentage, hazard ratio [HR], 1.004; 95% CI, 1.002-1.007; P < 0.001) and PSMA tumor volume (per unit, HR, 1.003; 95% CI, 1.000-1.005; P = 0.03). Multivariable Cox regression analysis confirmed ΔPSA (per percentage, HR, 1.004; 95% CI, 1.001-1.006; P = 0.006) as an independent prognosticator for OS. Kaplan-Meier analyses provided significant segregation between individuals with versus those without any PSA response (19 mo vs. 14 mo; HR, 2.00; 95% CI, 0.95-4.18; P = 0.04). Differentiation between patients with or without progressive disease (PD) was also feasible when applying PSA-based PCWG3 (19 mo vs. 9 mo for non-PD and PD, respectively; HR, 2.29; 95% CI, 1.03-5.09; P = 0.01) but slightly failed when applying RECIP 1.0 (P = 0.08). A combination of both response systems (PCWG3 and RECIP 1.0), however, yielded the best discrimination between individuals without versus those with PD (19 mo vs. 8 mo; HR, 2.78; 95% CI, 1.32-5.86; P = 0.002). Conclusion: In patients with mCRPC treated with RLT and imaged with [18F]PSMA-1007, frameworks integrating both the biochemical (PCWG3) and PET-based response (RECIP 1.0) may best assist in identifying subjects prone to disease progression.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hartrampf PE, Hüttmann T, Seitz AK, et al. Prognostic Performance of RECIP 1.0 Based on [18F]PSMA-1007 PET in Prostate Cancer Patients Treated with [177Lu]Lu-PSMA I&T. J Nucl Med. 2024. PMID: 38453363. doi:10.2967/jnumed.123.266702

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。